scholarly journals Apples, oranges, and anything in between: In search of the best desensitization therapy

2021 ◽  
Author(s):  
Carrie A. Schinstock ◽  
Anat R Tambur
Keyword(s):  
Desensitization Therapy

scholarly journals Daratumumab for Desensitization Therapy in Lung Transplant Candidates

2021 ◽  
Vol 40 (4) ◽  
pp. S335
Author(s):  
G. Magda ◽  
A.L. Ramsey ◽  
R. Saggar ◽  
M.Y. Shino ◽  
S.S. Weigt ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Desensitization Therapy ◽  
Transplant Candidates

Abstract 16877: Correlation of Antibody Binding Strength to Complement Fixation

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Vishal Y Parikh ◽  
Nancy Reinsmoen ◽  
Jignesh Patel ◽  
Zhe Yu ◽  
Frank Liou ◽  
...  
Keyword(s):  
Fluorescence Intensity ◽  
Heart Transplant ◽  
Binding Assay ◽  
Complement Fixation ◽  
Antibody Binding ◽  
Binding Ability ◽  
Binding Strength ◽  
Desensitization Therapy ◽  
Positive Rate ◽  
Correlation Statistics

Background: In patients (pts) who are highly sensitized, desensitization therapy is commonly applied to reduce antibody (Abs) load and to reduce potential morbidity and mortality following heart transplant (HTx). It is not known as to what level of antibody binding is needed to initiate desensitization therapy. It is believed that high binding Abs may have the ability to fix complement and lead to cytotoxicity. Methods: Between 2011 and 2012 we assessed 13 highly sensitized pts who were noted to have standardized fluorescence intensity (SFI) >100,000 pretransplant. A complement binding assay (C1q binding assay) was then applied to these Abs to assess for a correlation of binding to cytotoxicity. Correlation statistics were used to derive significance between higher antibody binding and capacity to bind complement. Results: There seems to be no correlation between the different binding strength and C1q positivity. However, when evaluating Luminex 1:8 test, there seems to be correlation between class I binding strength with C1q positivity. There was C1q positive rate of 10.8% in SFI 200,000 range. Conclusions: Undiluted antibodies do not correlate to C1q binding ability. However the 1:8 dilution test seems to provide an better prediction of complement binding. 1:8 dilutions should be performed to accurately assess the ability for antibodies to bind complement.

Reply to “Defining the Benefits of Desensitization Therapy”

2013 ◽  
Vol 95 (6) ◽  
pp. e33 ◽  
Author(s):  
Andrew L. Singer ◽  
Nada Alachkar ◽  
Robert A. Montgomery ◽  
Andrea A. Zachary
Keyword(s):  
Desensitization Therapy

Clinical study on combined acupuncture and psychological desensitization therapy for anxiety due to heroin addiction

2010 ◽  
Vol 8 (2) ◽  
pp. 116-118 ◽  
Author(s):  
Xiao-ge Song ◽  
Ling Hu ◽  
Rong-lin Cai ◽  
Yi-bin Mei ◽  
Xiao-ting Li
Keyword(s):  
Clinical Study ◽  
Heroin Addiction ◽  
Desensitization Therapy

Systemic Nickel Allergy: Oral Desensitization and Possible Role of Cytokines Interleukins 2 and 10

2013 ◽  
Vol 26 (1) ◽  
pp. 251-257 ◽  
Author(s):  
L. Ricciardi ◽  
A. Carnì ◽  
G. Loschiavo ◽  
S. Gangemi ◽  
V. Tigano ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Oral Tolerance ◽  
Challenge Test ◽  
Gastrointestinal Symptoms ◽  
Oral Immunotherapy ◽  
Nickel Allergy ◽  
Oral Challenge Test ◽  
Before And After ◽  
Desensitization Therapy ◽  
Oral Desensitization

Nickel ingested with food can elicit either systemic cutaneous or gastrointestinal symptoms causing a systemic nickel allergy syndrome (SNAS) that can be treated with tolerance by oral ingestion of the metal. It has been suggested that interleukins 2 (IL-2) and 10 (IL-10) are involved in the mechanisms underlying oral tolerance. We evaluated the clinical efficacy of oral desensitization therapy in SNAS consisting in the administration of nickel sulphate. Because nickel allergy prevalently affects women, only female subjects (N = 22) were recruited. Oral nickel desensitizing therapy was associated with low-nickel diet for three months. Before and after therapy, clinical conditions were evaluated, and circulating cytokines IL-2 and IL-10 were measured. After the two-year treatment, visual analogue scale (VAS) scores for symptoms were significantly reduced (P < 0.001). Patients were released by either cutaneous or gastrointestinal symptoms and by tolerating nickel-containing food. At the end of the treatment, nickel oral challenge test was negative in 18 patients, and IL-2 level in the serum was significantly reduced while IL-10 was increased, although this datum was not statistically significant. Our study confirms the clinical efficacy of nickel oral immunotherapy and focuses on the mechanisms triggered by oral tolerance indicating that reduction of IL-2 can be associated with success of oral nickel desensitizing therapy.

scholarly journals Desensitization Therapy for Patients with DSA Receiving Haploidentical (Haplo) Stem Cell Transplantation

2020 ◽  
Vol 26 (3) ◽  
pp. S296-S297
Author(s):  
Stefan O. Ciurea ◽  
Piyanuch Kongtim ◽  
Jun Zou ◽  
Fleur Aung ◽  
Ketevan Gendzekhadze ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Desensitization Therapy

Hypnosis and the Desensitization Behavior Therapies

1970 ◽  
Vol 27 (3) ◽  
pp. 787-794 ◽  
Author(s):  
Stuart B. Litvak
Keyword(s):  
Systematic Desensitization ◽  
Desensitization Therapy ◽  
Mental Operations

A distinction is made between desensitization techniques carried out in vivo and other modes of desensitization therapy (flooding, implosion, and systematic desensitization) which rely upon mental operations or processes. Research is reviewed and points are discussed which support a position supporting a relationship between variables and phenomena found in the desensitization therapies and those found in hypnosis. This relationship appears to be greatest in those desensitization therapies basing treatment upon the utilization of mental operations. Some new lines of research are then proposed.

Sign in / Sign up

Export Citation Format

Share Document